论文部分内容阅读
目的探讨分析不同尿激酶用量经导管溶栓(CDT)治疗的下肢深静脉血栓形成(DVT)患者的疗效。方法选取2011年12月~2013年12月在我院确诊收治的100例DVT患者。将所有患者随机分成2组接受CDT治疗:观察组使用中等剂量的尿激酶溶酸(日用量30~60万U),对照组使用大剂量的尿激酶溶酸(日用量>60万U)。观察两组的溶栓时间、溶栓效果。结果两组溶栓疗效差异显著(P<0.05),观察组和对照组疗效差异显著(P<0.05)。两组溶栓时间差异显著(P<0.05)。结论采用CDT治疗DVT时尿激酶日用量在30万U~60万U最好,具有较高的临床应用价值,安全可靠,疗效确切,值得临床大力推广。
Objective To investigate the curative effect of different doses of urokinase on patients with deep vein thrombosis (DVT) treated by catheterized thrombolysis (CDT). Methods A total of 100 DVT patients diagnosed in our hospital from December 2011 to December 2013 were selected. All patients were randomly divided into two groups receiving CDT treatment: the observation group using a moderate dose of urokinase dissolved acid (daily use of 30 to 600000 U), the control group using high-dose urokinase lysozyme (600000 U). Thrombolytic time and thrombolytic effect were observed in both groups. Results The curative effect of thrombolysis was significant difference between the two groups (P <0.05). There was significant difference between the observation group and the control group (P <0.05). There was significant difference between the two groups in the thrombolytic time (P <0.05). Conclusions The daily dosage of urokinase in CDT with DVT is 300,000 U ~ 600,000 U, which is of high clinical value, safe, reliable and effective. It is worth clinical promotion.